Intended for healthcare professionals


Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations

BMJ 2006; 333 doi: (Published 14 September 2006) Cite this as: BMJ 2006;333:603
  1. Richard J Phillips, pharmaceutical consultant1 (,
  2. Nick Bosanquet, professor of health policy2
  1. 1 Goffin Consultancy, Stelling Minnis, Canterbury, Kent CT4 6AZ
  2. 2 Imperial College, London

    EDITOR—We have concerns with some of the points raised by Pelosi et al in accepting the economic model used by the National Institute for Health and Clinical Excellence (NICE) for its current draft guidance on cholinesterase inhibitors.1 There are serious and acknowledged limitations and uncertainties in the economic analysis performed by NICE.2

    The model developers admit the model structure …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription